Related Experiment Video
Updated: Jun 11, 2025
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
Published on: March 7, 2017
EZHIP's role in diffuse midline glioma: echoes of oncohistones?
Afraah Cassim1, Matthew D Dun2, David Gallego-Ortega3
1Cancer Epigenetic Biology and Therapeutics Laboratory, Children's Cancer Institute, Lowy Cancer Centre, Kensington, New South Wales, Australia; School of Biomedical Engineering, Faculty of Engineering and IT, University of Technology Sydney, New South Wales, Australia.
Abstract:
The enhancer of zeste inhibitory protein (EZHIP) is typically expressed during germ cell development and has been classified as a cancer-testis antigen (CTA) in various cancers. In 2020, 4% of diffuse midline gliomas (DMGs) were shown to aberrantly express EZHIP, mirroring the DMG hallmark histone H3 K27M (H3K27M) oncohistone mutation. Similar to H3K27M, EZHIP is a negative regulator of polycomb repressive complex 2 (PRC2), leading to global epigenomic remodeling. In this opinion, we explore the similarities and disparities between H3K27M- and EZHIP-DMGs with a focus on their shared functional hallmark of PRC2 inhibition, their genetic and epigenomic landscapes, plausible differences in the cell of origin, and therapeutic avenues. Upcoming research on EZHIP will help better understand its role in gliomagenesis and DMG therapy.
Insights
Enhancer of zeste inhibitory protein (EZHIP) aberrant expression in diffuse midline gliomas (DMGs) mirrors histone H3 K27M mutations. Both EZHIP and H3K27M inhibit PRC2, impacting epigenomic landscapes and offering potential therapeutic targets for DMGs.
Area of Science:
- Oncology
- Epigenetics
- Neuro-oncology
Background:
- Enhancer of zeste inhibitory protein (EZHIP) is a cancer-testis antigen (CTA).
- Aberrant EZHIP expression occurs in 4% of diffuse midline gliomas (DMGs), similar to the histone H3 K27M (H3K27M) mutation.
- EZHIP, like H3K27M, negatively regulates polycomb repressive complex 2 (PRC2), causing global epigenomic changes.
Purpose of the Study:
- To compare and contrast H3K27M-mutant and EZHIP-aberrantly expressing DMGs.
- To focus on the shared PRC2 inhibition hallmark.
- To explore genetic/epigenomic landscapes, cell of origin differences, and therapeutic strategies.
Main Methods:
- Comparative analysis of H3K27M and EZHIP in DMGs.
- Review of genetic and epigenomic data.
- Discussion of potential cell of origin and therapeutic implications.
Main Results:
- EZHIP and H3K27M share the functional hallmark of PRC2 inhibition.
- Both alterations lead to global epigenomic remodeling in DMGs.
- Potential differences in cell of origin and therapeutic avenues exist between these DMG subtypes.
Conclusions:
- EZHIP represents a significant finding in DMG research, mirroring H3K27M's role.
- Understanding EZHIP's function is crucial for advancing DMG gliomagenesis insights and therapy.
- Further research on EZHIP will illuminate its role in tumorigenesis and treatment strategies for DMGs.
Related Concept Videos
01:22Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
02:33Hedgehog Signaling Pathway